MESO: Mesoblast Ltd insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
72 institutions reported holding $53.17M of Mesoblast Ltd on Form 13F (69 the quarter before). 9 opened a new position and 6 sold out. Shares held by institutions: +19%.
| Largest holders | Shares | Value |
|---|---|---|
| MORGAN STANLEY | 718,608 | $9.72M |
| BlackRock, Inc. | 664,280 | $8.99M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 457,744 | $6.19M |
| GOLDMAN SACHS GROUP INC | 395,612 | $5.35M |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 259,700 | $3.51M |
| UBS Group AG | 200,053 | $2.71M |
| Arax Advisory Partners | 168,022 | $2.27M |
| BANK OF AMERICA CORP /DE/ | 100,000 | $1.35M |
| Penbrook Management LLC | 87,075 | $1.18M |
| Fi3 FINANCIAL ADVISORS, LLC | 7,891 | $1.02M |
Clinical trial readouts
1 Phase 2 or 3 trials by Mesoblast Ltd with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-07 (est.) | Rexlemestrocel-L + HA mixture | Degenerative Disc Disease | Phase 3 | 300 | Enrollment complete | NCT06325566 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.